To assess the potential hazards of nitrazepam therapy of insomnia in the elderly, adverse reactions to nitrazepam were studied in 2111 hospitalized medical patients who received the drug. 2 Manifestations of unwanted central nervous system (CNS) depression (such as drowsiness or 'hangover') were reported in 49 nitrazepam recipients (2.3%), and signs of unwanted CNS stimulation (such as nightmares, insomnia, agitation, etc.) in 15 (0.7%). None of the adverse reactions were considered serious. 3 Physician-rated clinical efficacy of nitrazepam was not related to dose, but the frequency of both types of adverse reactions increased significantly at higher daily doses. CNS depression also was significantly more frequent in the elderly, being reported in 11% of those aged 80 years or older, whereas the frequency of CNS stimulation was not correlated with age. 4 The effect of age on the reported rate of unwanted CNS depression was most striking at high doses. Among patients aged 80 years or over whose daily dose averaged 10 mg or more, 55% experienced unwanted CNS depression attributed to nitrazepam. 
Introduction Methods
The extensive prescribing of psychotropic drugs for elderly patients has generated considerable concern (Learoyd, 1972 (Learoyd, , 1974 Dawson-Butterworth, 1970; Chapman, 1976 (Greenblatt & Shader, 1974) , but recent reports suggest that the drug presents a hazard to certain elderly individuals (Evans & Jarvis, 1972; Harenko, 1975; Castleden, George & Mercer, 1977) . Previous studies from the Boston Collaborative Drug Surveillance Program (BCDSP) indicate an increased frequency of adverse reactions to three other benzodiazepine derivatives-chlordiazepoxide, diazepam and flurazepam-in elderly patients (Boston Collaborative Drug Surveillance Program, 1973; Greenblatt, Allen & Shader, 1977) . The present report assesses the influence of age upon patterns of clinical toxicity attributed to nitrazepam among a large series of hospitalized medical patients who received the drug.
The scope and operation of the Boston Collaborative Drug Surveillance Program (BCDSP) have been described previously (Jick, 1974; Allen & Greenblatt, 1975; Miller & Greenblatt, 1976) . Trained nursemonitors stationed on medical wards use standardized self-coding sheets to record information on consecutively admitted patients. Data are collected on patient characteristics, diagnoses, the therapeutic efficacy of all drugs administered, details of dosage, and duration of therapy. When drug therapy is instituted, the prescribing physician is interviewed to determine the therapeutic indications; reasons for termination of therapy and descriptions of possible adverse reactions are recorded as weLL For each suspected adverse reaction, the attending physician judges the likelihood that the drug caused the adverse reaction. An independent second judgement is later rendered by a clinical pharmacologist who reviews the case.
This report is based on data accumulated between 1969 and 1976 on 11,000 hospitalized medical patients in Israel, Scotland, New Zealand, Germany and Italy, of whom 2111 (19.2%) received nitrazepam.
Results

Patient characteristics
The mean age of the 2111 nitrazepam recipients was 57 years, and nearly 50% were aged 60 years or older (Table 1) . Only 5% died while in the hospital (Table  1) . Cardiovascular disease was the primary (first) diagnosis in 51% of patients.
Nitrazepam therapy a total dose of less than 20 mg, but 26% received 100 mg or more (Table 2) . Since most individuals received the drug on an intermittent or pxr.n. basis, it was useful to compute for each patient an 'average' daily dose, as the quotient of the total dose and the number of days of therapy. The average daily dose calculated by this method was less than 5 mg per day in 30% of cases (Table 2) .
The clinical efficacy of nitrazepam, as judged by attending physicians, was unsatisactory in 7.5% of cases. Unsatisfactory ratings were similar in frequency regardless of the size of the administered dose ( (Table 3) was not sufficient to evaluate the effect ofdose. (Figure 1 ).
Interaction of dose and age Stratification of dosage levels within each age group indicated that the influence of dose upon the frequency of unwanted CNS depression was most obvious in the elderly (Figure 2 ). (Table 4 ). Unwanted effects also were significantly more common among patients with long hospitalizations and in those who died ( (Miller & Greenblatt, 1976 (Miller & Greenblatt, 1976) . Nightmares have been associated with nitrazepam therapy in several reports in the literature (Meares, Mills & Oliver, 1972; Taylor, 1973; Girdwood, 1973; Goossens, Bulckaert & Wakeling, 1973) . Furthermore, 'paradoxical' CNS stimulation, including agitation, hyperactivity, and aggressive behavior, is commonly observed among children receiving anticonvulsant therapy with clonazepam, a 7-nitro-substituted benzodiazepine derivative closely related to nitrazepam in structure (Browne, 1976) . The findings suggest that nitrosubstitution at the 7-position may render benzodiazepine derivatives more likely to produce unwanted CNS stimulation.
Unsatisfactory hypnotic efficacy of nitrazepam was reported in only 7.5% of cases in which a judgement of efficacy was made. The frequency of unsatisfactory ratings did not become smaller as the dose increased. Again, this contrasts with the results of the flurazepam study , in which unsatisfactory ratings were significantly more frequent among patients receiving lower doses. It should be emphasized that the present study was not a prospective controlled trial, and the findings may in part reflect a tendency for physicians to administer higher doses of nitrazepam to patients with more severe insomnia. However, it is likely that the hypnotic efficacy of 5 and 10 mg doses of nitrazepam is approximately equivalent. This is consistent with controlled clinical trials which demonstrate only subtle differences in hypnotic efficacy between the two dose levels of nitrazepam (le Riche, Csima & Dobson, 1966; Malpas, Rowan & Joyce, 1970; Malpas, Legg & Scott, 1974) .
On the other hand, the two major types of adverse reactions to nitrazepam clearly were dose-related in frequency. Numerous clinical studies demonstrate an increased frequency of unwanted CNS depression and/or impairment of psychomotor performance at higher doses of nitrazepam (le Riche et al., 1966; Malpas & Joyce, 1969; Malpas et al., 1970; Walters & Lader, 1971; Malpas, 1972; Adams, 1974; Borland & Nicholson, 1974; Momose, Ishii & Kuge, 1976) . We observed that unwanted CNS stimulation also became more frequent at higher nitrazepam doses, suggesting that such reactions are not necessarily unpredictable or 'idiosyncratic'.
Unwanted CNS depression attributed to nitrazepam was substantially more frequent among the elderly, particularly in patients aged 70 years or older. A similar association of toxicity with increasing age has been reported in BCDSP studies of other benzodiazepine derivatives (chlordiazepoxide (BCDSP, 1973) , diazepams (BCDSP, 1973) , and flurazepam ), but has not been observed in the BCDSP data for nonbenzodiazepine hypnotics such as chloral hydrate and barbiturates (Miller & Greenblatt, 1976) . Examination of the interaction of dose and age indicated that the higher incidence of nitrazepam-attributed CNS depression in the elderly was evident only at high doses of nitrazepam. At low doses, such reactions were rare regardless of age. The hazards of nitrazepam in the elderly, particularly at high doses, have been observed by others (Evans & Jarvis, 1972; Harenko, 1975; Castleden et aL, 1977 ). There appears to be little reason to initiate nitrazepam therapy with 10 mg doses in most patients, and certainly not in the elderly. Doses of 5 mg provide approximately equivalent hypnotic efficacy, with a substantially reduced frequency of unwanted drowsiness, hangover, and other manifestations of undesired CNS depression.
In contrast to adverse reactions related to CNS depression, age per se had little influence on the frequency of unwanted CNS stimulation. According to traditional teaching, elderly individuals are particularly susceptible to 'paradoxical' stimulation due to hypnotic drug administration (Gibson, 1966; Dawson-Butterworth, 1970; Learoyd, 1972) . Our data on nitrazepam, however, suggest that dose rather than age is the major determinant of such reactions.
The present study does not establish whether the increased toxicity of nitrazepam in the elderly is due to a greater sensitivity of the ageing brain to effects of the drug, or to age-related changes in pharmacokinetics which lead to greater accumulation of the drug in brain. Studies of other benzodiazepines suggest that important pharmacokinetic changes can occur with age. Clearance of chlordiazepoxide is reduced in elderly as opposed to young male volunteers (Shader, Greenblatt & Harmatz, 1977) . Studies of diazepam reveal longer values of elimination half-life associated with age, but no significant age-related change in clearance (Klotz, Avant & Hoyumpa, 1975 ).
Nitrazepam clearance is accomplished largely by reduction of the 7-nitro substitution, followed by acetylation (Greenblatt & Shader, 1974; Reider & Wendt, 1973) . The acetylation reaction is genetically polymorphic (Karin & Price-Evans, 1976 ), but a recent study suggested that age as such had no significant influence on nitrazepam elimination (Castleden et al., 1977) . Adverse reactions to nitrazepam were more frequent among individuals who died, in those with long hospitalizations, and in those with elevated blood urea nitrogen concentrations on admission. These associations probably reflect a general tendency for adverse drug reactions to occur more frequently among more seriously ill patients (Miller & Greenblatt, 1976) . Since renal clearance contributes very little to the total metabolic clearance of nitrazepam, it is unlikely that renal insufficiency in itself causes increased accumulation of nitrazepam. However, renal disease can influence drug distribution, possibly through a change in the extent of drug protein-binding (Koch-Weser & Sellers, 1976 (Arndt & Jick, 1976) .
